322 related articles for article (PubMed ID: 25287069)
21. Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis.
Hagberg Thulin M; Nilsson ME; Thulin P; Céraline J; Ohlsson C; Damber JE; Welén K
Mol Cell Endocrinol; 2016 Feb; 422():182-191. PubMed ID: 26586211
[TBL] [Abstract][Full Text] [Related]
22. Estradiol and raloxifene induce the proliferation of osteoblasts through G-protein-coupled receptor GPR30.
Noda-Seino H; Sawada K; Hayakawa J; Ohyagi-Hara C; Mabuchi S; Takahashi K; Nishio Y; Sakata M; Kurachi H; Kimura T
J Endocrinol Invest; 2013 Jan; 36(1):21-7. PubMed ID: 22453024
[TBL] [Abstract][Full Text] [Related]
23. Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis.
Xiao L; Wang Y; Xu K; Hu H; Xu Z; Wu D; Wang Z; You W; Ng CF; Yu S; Chan FL
Cancer Res; 2018 May; 78(9):2205-2218. PubMed ID: 29438990
[TBL] [Abstract][Full Text] [Related]
24. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
[TBL] [Abstract][Full Text] [Related]
25. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.
Rajan P; Sudbery IM; Villasevil ME; Mui E; Fleming J; Davis M; Ahmad I; Edwards J; Sansom OJ; Sims D; Ponting CP; Heger A; McMenemin RM; Pedley ID; Leung HY
Eur Urol; 2014 Jul; 66(1):32-9. PubMed ID: 24054872
[TBL] [Abstract][Full Text] [Related]
26. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract][Full Text] [Related]
27. Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Wong N; Major P; Kapoor A; Wei F; Yan J; Aziz T; Zheng M; Jayasekera D; Cutz JC; Chow MJ; Tang D
Oncotarget; 2016 Dec; 7(50):83115-83133. PubMed ID: 27825118
[TBL] [Abstract][Full Text] [Related]
28. The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling.
Correa RG; Krajewska M; Ware CF; Gerlic M; Reed JC
Oncotarget; 2014 Mar; 5(6):1666-82. PubMed ID: 24681825
[TBL] [Abstract][Full Text] [Related]
29. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
30. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
[TBL] [Abstract][Full Text] [Related]
31. A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer.
Dahiya NR; Chandrasekaran B; Kolluru V; Ankem M; Damodaran C; Vadhanam MV
Mol Carcinog; 2018 Oct; 57(10):1332-1341. PubMed ID: 30069922
[TBL] [Abstract][Full Text] [Related]
32. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
33. Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion.
Shih TC; Liu R; Wu CT; Li X; Xiao W; Deng X; Kiss S; Wang T; Chen XJ; Carney R; Kung HJ; Duan Y; Ghosh PM; Lam KS
Clin Cancer Res; 2018 Sep; 24(17):4319-4331. PubMed ID: 29666302
[No Abstract] [Full Text] [Related]
34. Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.
Gowda PS; Deng JD; Mishra S; Bandyopadhyay A; Liang S; Lin S; Mahalingam D; Sun LZ
Mol Cancer Res; 2013 Nov; 11(11):1448-61. PubMed ID: 23989930
[TBL] [Abstract][Full Text] [Related]
35. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
36. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
[TBL] [Abstract][Full Text] [Related]
37. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
[TBL] [Abstract][Full Text] [Related]
38. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
[TBL] [Abstract][Full Text] [Related]
39. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.
Ariazi EA; Brailoiu E; Yerrum S; Shupp HA; Slifker MJ; Cunliffe HE; Black MA; Donato AL; Arterburn JB; Oprea TI; Prossnitz ER; Dun NJ; Jordan VC
Cancer Res; 2010 Feb; 70(3):1184-94. PubMed ID: 20086172
[TBL] [Abstract][Full Text] [Related]
40. SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.
Liu C; Wang C; Wang K; Liu L; Shen Q; Yan K; Sun X; Chen J; Liu J; Ren H; Liu H; Xu Z; Hu S; Xu D; Fan Y
J Natl Cancer Inst; 2013 Nov; 105(22):1719-28. PubMed ID: 24174655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
